TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease
Brief Summary: The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
C: Intervention Type: DRUG; Name: EPAX 1050TG; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease
Brief Summary: The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).


Options:
A: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Disease Management for Smokers in Rural Primary Care
Brief Summary: The primary aim of this study is to assess the effectiveness of both high and low intensity, disease management programs for smoking. The hypotheses are to compare abstinence from cigarettes, the number of quit attempts, and smokers motivation at 24 months between participants receiving high and low intensity disease management and those receiving usual care.


Options:
A: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Arm Label: Extended Care Management; Type: EXPERIMENTAL; Interventions: Other: Extended Care Management | Intervention Type: OTHER; Name: Extended Care Management; Assigned to Arm(s): Extended Care Management | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Arm Label: Proactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Arm Label: Reactive group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Behavioral: Tobacco Quit Line Program | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Proactive group, Reactive group | Intervention Type: BEHAVIORAL; Name: Tobacco Quit Line Program; Assigned to Arm(s): Proactive group, Reactive group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prevention Consult; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prevention Consult | Arm Label: Consult & Behavioral Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Consult & Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Prevention Consult; Assigned to Arm(s): Prevention Consult | Intervention Type: BEHAVIORAL; Name: Consult & Behavioral Intervention; Assigned to Arm(s): Consult & Behavioral Intervention
D: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Disease Management for Smokers in Rural Primary Care
Brief Summary: The primary aim of this study is to assess the effectiveness of both high and low intensity, disease management programs for smoking. The hypotheses are to compare abstinence from cigarettes, the number of quit attempts, and smokers motivation at 24 months between participants receiving high and low intensity disease management and those receiving usual care.


Options:
A: Arm Label: Enhanced PTSD Health Buddy and Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Interviewing Counseling | Arm Label: Usual PTSD Health Buddy Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation Interviewing Counseling; Assigned to Arm(s): Enhanced PTSD Health Buddy and Motivational Interviewing
B: Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice (BA) | Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education (HE) | Intervention Type: BEHAVIORAL; Name: Brief Advice (BA); Assigned to Arm(s): Brief Advice | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Health Education (HE); Assigned to Arm(s): Health Education
C: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Brief Advice (SBA) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Structured Brief Advice (SBA); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Disease Management for Smokers in Rural Primary Care
Brief Summary: The primary aim of this study is to assess the effectiveness of both high and low intensity, disease management programs for smoking. The hypotheses are to compare abstinence from cigarettes, the number of quit attempts, and smokers motivation at 24 months between participants receiving high and low intensity disease management and those receiving usual care.


Options:
A: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches
B: Arm Label: High intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: High intensity disease management, Drug: Bupropion | Arm Label: Low intensity disease management; Type: EXPERIMENTAL; Interventions: Behavioral: Low intensity disease management, Drug: Bupropion | Arm Label: Comparison group; Type: OTHER; Interventions: Behavioral: Comparison group, Drug: Bupropion | Intervention Type: BEHAVIORAL; Name: High intensity disease management; Assigned to Arm(s): High intensity disease management | Intervention Type: BEHAVIORAL; Name: Low intensity disease management; Assigned to Arm(s): Low intensity disease management | Intervention Type: BEHAVIORAL; Name: Comparison group; Assigned to Arm(s): Comparison group | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Comparison group, High intensity disease management, Low intensity disease management
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Lifestyle Counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer
Brief Summary: The purpose of the study is to evaluate the effect of the study drug (GW679769) on a commonly used chemotherapy drug (docetaxel) which will be given I.V. Blood samples will be taken to see if the GW679769 alters the blood levels of the chemotherapy. The study will last about 2 weeks with a final follow-up visit 6 weeks later.


Options:
A: Arm Label: Aprepitant; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant/Ramosetron/Dexamethasone | Intervention Type: DRUG; Name: Aprepitant/Ramosetron/Dexamethasone; Assigned to Arm(s): Aprepitant
B: Arm Label: 1; Type: OTHER; Interventions: Drug: aprepitant, Drug: Comparator: ondansetron, Drug: Comparator: dexamethasone, Drug: Comparator; Placebo (unspecified) | Arm Label: 2; Type: OTHER; Interventions: Drug: Comparator: ondansetron, Drug: Comparator: dexamethasone, Drug: Comparator: fosaprepitant dimeglumine, Drug: Comparator; Placebo (unspecified) | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: ondansetron; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: dexamethasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: fosaprepitant dimeglumine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator; Placebo (unspecified); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator; Placebo (unspecified); Assigned to Arm(s): 2
C: Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Arm Label: Docetaxel/Casopitant; Type: EXPERIMENTAL; Interventions: Drug: Casopitant/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel | Intervention Type: DRUG; Name: Casopitant/Docetaxel; Assigned to Arm(s): Docetaxel/Casopitant
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: fosaprepitant dimeglumine, Drug: Dexamethasone, Drug: Ondansetron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Aprepitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Comparator: fosaprepitant dimeglumine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Aprepitant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer
Brief Summary: This crossover trial is performed in advanced and metastatic pancreatic cancer not previously exposed to chemotherapy. The study compares a standard arm with gemcitabine plus erlotinib to an experimental arm with capecitabine plus erlotinib. It is the first trial of its kind to incorporate second-line treatment into the study design. Patient who fail on first-line therapy are switched to the comparator chemotherapy without erlotinib. The trial therefore not only compares two different regimens of first-line treatment, it also compares two sequential treatment strategies.


Options:
A: Arm Label: 1. Gemcitabine monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gemcitabine | Arm Label: 2. Gemcitabine plus AGS-1C4D4; Type: EXPERIMENTAL; Interventions: Biological: AGS-1C4D4, Biological: Gemcitabine | Intervention Type: BIOLOGICAL; Name: AGS-1C4D4; Assigned to Arm(s): 2. Gemcitabine plus AGS-1C4D4 | Intervention Type: BIOLOGICAL; Name: Gemcitabine; Assigned to Arm(s): 1. Gemcitabine monotherapy, 2. Gemcitabine plus AGS-1C4D4
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: docetaxel, Radiation: radiation therapy | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+erlotinib | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine+erlotinib+capecitabine | Intervention Type: DRUG; Name: Gemcitabine+erlotinib; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Gemcitabine+erlotinib+capecitabine; Assigned to Arm(s): Experimental
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Erlotinib | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Erlotinib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A, Arm B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).


Options:
A: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
B: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
B: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)

Answer: C